BioSpace News Archive

Though data became an issue in two separate meetings, the FDA’s Oncologic Drugs Advisory Committee made a potentially precedent-setting decision by voting in favor of US WorldMeds’ neuroblastoma treatment.

Verona Pharma plc, announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 - 10:00 AM ET.

UNION therapeutics A/S announced acceptance of a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress 2023 on October 11-14, 2023, in Berlin, Germany.

Asceneuron SA announced the appointment of Barbara Angehrn Pavik as the new Chief Executive Officer, as part of a leadership transition poised to propel the company into its next phase of growth, with two compounds in clinical development.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires.

Cybin Inc. today announced that its abstract describing a comprehensive structure-activity relationship study of a series of novel serotonergic phenethylamines has been selected for presentation at the Neuropsychiatric Drug Development Summit taking place October 11-12 in Boston, MA.

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK4/6 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”) will present at the 8th Annual Dawson James Conference on Thursday, October 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida.

Locanabio, Inc. today announced the presentation of data demonstrating the packaging and delivery of its proprietary small nuclear RNA (snRNA) platform using adeno-associated virus (AAV).

Arcutis Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis.